Opinion|Videos|November 19, 2024
Safety Profiles of Neurokinin-Targeted Therapies for VMS
Key Takeaways
- Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to other treatments.
- The trials highlighted elinzanetant's positive impact on quality of life for women with severe VMS.
Panelists discuss the notable adverse events observed in the OASIS trials with elinzanetant and compare the safety profiles of elinzanetant and fezolinetant with those of traditional treatments for vasomotor symptoms (VMS).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant?
- (FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
US Employer Health Care Costs Projected to Rise 9.5% in 2027
2
5 Things to Know About the FDA's Peptide Reversal
3
Rural Patients Face Gaps in Hospice Access, Care Intensity
4
5 Things to Know About Chronic Hand Eczema and Its Evolving Treatment Landscape
5